Cancer Stem Cell News Volume 10.06 | Feb 17 2021

    By
    Justin.choi
    -
    0
    330







    2021-02-17 | CSCN 10.06


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.06 – 17 February, 2021
    TOP STORY

    PRMT5 Inhibition Disrupts Splicing and Stemness in Glioblastoma

    Using two orthogonal-acting inhibitors of Protein arginine methyltransferase 5 (PRMT5), researchers showed that pharmacological inhibition of PRMT5 suppressed the growth of a cohort of 46 patient-derived glioblastoma stem cell cultures, with the proneural subtype showing greater sensitivity.
    [Nature Communications]

    Full Article

    How can evaluating the immuno-oncology potential of compounds in vitro predict clinical outcomes? Watch this webinar by Dr. Alison O'Mahony, Eurofins DiscoverX
    PUBLICATIONSRanked by the impact factor of the journal

    Tumor Cell Plasticity, Heterogeneity, and Resistance in Crucial Microenvironmental Niches in Glioma

    The authors identified NOTCH1 as a central switch between the perivascular niche and network niche in glioma, and demonstrated robust cross-compensation when only one niche was targeted.
    [Nature Communications]

    Full Article

    YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer

    Scientists showed that the receptor tyrosine kinase Met promoted YAP activity in basal-like breast cancer and found enhanced YAP activity within the CSC population.
    [Cancer Research]

    Abstract

    Reprogramming Transcription Factors Oct4 and Sox2 Induces a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells

    Induction and function of BRD/H3k27Ac-dependent immunosuppressive genes played a role in the immunosuppressive phenotype of stem-like tumor-propagating cells in GBM.
    [Cancer Research]

    Abstract

    Regulatory T Cells Promote Glioma Cell Stemness through TGF-β–NF-κB–IL6–STAT3 Signaling

    Mechanistic investigations indicated that TGF-β acted on cancer cells to induce the core cancer stem cell-related genes CD133, SOX2, NESTIN, MUSASHI1 and ALDH1A expression and spheres formation via NF-κB–IL6–STAT3 signaling pathway, resulting in the increased cancer stemness and tumorigenic potential.
    [Cancer Immunology Immunotherapy]

    Full Article

    Alpha-Enolase (ENO1), Identified as an Antigen to Monoclonal Antibody 12C7, Promotes the Self-Renewal and Malignant Phenotype of Lung Cancer Stem Cells by AMPK/mTOR Pathway

    Immunofluorescence was used for antigen localization. After targeted antigen purification by electrophoresis and immunoblot, the antigen was identified by LC-MALDI-TOF/TOF mass spectrometry, immunofluorescence, and immunoprecipitation.
    [Stem Cell Research & Therapy]

    Full Article

    The Combination Effect of Prominin1 (CD133) Suppression and Oxaliplatin Treatment in Colorectal Cancer Therapy

    Scientists checked the combined effect of CD133 siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of olorectal cancer cells in the HT-29 cell line.
    [Biomedicine & Pharmacotherapy]

    Full ArticleGraphical Abstract

    Macrophages Support the Aggressive Mechanical Phenotype of Circulating Tumor Cells in Prostate Cancer

    Investigators recapitulated the tumor cells-macrophages interactions in cell culture using prostate cancer cell lines.
    [Biophysical Journal]

    Abstract

    Exploitation of the Vitamin A/Retinoic Acid Axis Depletes ALDH1-Positive Cancer Stem Cells and Re-Sensitises Resistant Non-Small Cell Lung Cancer Cells to Cisplatin

    The authors investigated the function of the CSC marker aldehyde dehydrogenase in retinoic acid cell signaling using an in vitro model of cisplatin resistant non-small cell lung cancer.
    [Translational Oncology]

    Full Article
    Survey Report: Where Is Pluripotent Stem Cell Research Now?
    REVIEWS

    Targeting Cancer Stem Cells for Reversing Therapy Resistance: Mechanism, Signaling, and Prospective Agents

    Investigators review the identification of CSCs, the intrinsic and extrinsic mechanisms of therapy resistance in CSCs, the signaling pathways of CSCs that mediate treatment failure, and potential CSC-targeting agents in various tumors from the clinical perspective.
    [Signal Transduction and Targeted Therapy]

    Full Article

    Mitochondrial Dynamics in Cancer Stem Cells

    Many CSC phenotypes including metabolism, epithelial-to-mesenchymal transition, cellular signaling pathway activity, and others, arise from altered mitochondrial function and turnover, which are regulated by constant cycles of mitochondrial fusion and fission.
    [Cellular and Molecular Life Sciences]

    Abstract

    Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression

    Investigators recapitulate the multifaceted action exerted by focal adhesion kinase and its prognostic significance in breast cancer.
    [Cancers]

    Full Article
    INDUSTRY AND POLICY NEWS

    ORYZON Announces FDA Orphan Drug Designation Granted to iadademstat for Treatment of Acute Myeloid Leukemia

    Oryzon Genomics, S.A. announced that the FDA has granted Orphan Drug Designation to the company’s first-in-class LSD1 inhibitor iadademstat for the treatment of patients with acute myeloid leukemia.
    [Oryzon Genomics, S.A.]

    Press Release

    University of Pittsburgh School of Medicine Launches Neurological Imaging and Therapeutics Center

    The University of Pittsburgh School of Medicine announced the launch of the Alba Tull Center for Neuro Imaging and Therapeutics.The center will be dedicated to designing and expanding imaging technologies for patient care to produce a new, sophisticated understanding of the brain at the molecular level with the goal of developing anti-aging therapeutics.
    [University of Pittsburgh]

    Press Release
    FEATURED EVENT

    Lipidomics of Health and Disease

    March 24 – 26, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Hematopoietic Development

    Icahn School of Medicine at Mount Sinai – New York, New York, United States

    Postdoctoral Fellow – p53 and Metabolism

    The Francis Crick Institute – London, England, United Kingdom

    Postdoctoral Positions – Hematopoiesis, Leukemia, Cancer, Human Pluripotent Stem Cells

    Icahn School of Medicine at Mount Sinai – New York, New York, United States

    Postdoctoral Researcher – Mesenchymal Niche in Leukemia

    Karolinska Institutet – Flemingsberg, Sweden

    Postdoctoral Fellowship – Human Cancers

    Memorial Sloan Kettering Cancer Center – New York, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter